Interestingly, in the subgroup of patients with HER2-positive BC (n = 14), HER3-DXd was associated with remarkable clinical activity with ORR of 42.9%, DCR of 92.9%, and median PFS of 11.0 months[85]. This evidence concerns the gene ERBB3 and breast cancer.